Decreased bone mineral density and vertebral compression fractures in a young adult male with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH): Is CAH an unrecognized population at risk for glucocorticoid-induced osteoporosis?

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 1-2, 2010, Pages 179-187

  Loechner, Karen J ^a   Patel, Shipra ^a   Fordham, Lynne ^b   McLaughlin, James T ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

DXA; Glucocorticoids; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANDROSTENEDIONE; CALCIUM; CITRATE CALCIUM; CORTICOTROPIN; DEXAMETHASONE; ERGOCALCIFEROL; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; PARATHYROID HORMONE; PRASTERONE; PREDNISONE; STEROID 21 MONOOXYGENASE; TESTOSTERONE; VITAMIN D;

ACANTHOSIS NIGRICANS; ADULT; ARTICLE; BACKACHE; BEDTIME DOSAGE; BODY SURFACE; BONE DENSITY; CASE REPORT; COMPRESSION FRACTURE; CONGENITAL ADRENAL HYPERPLASIA; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY INTERVENTION; FAMILY HISTORY; FOLLOW UP; GYNECOMASTIA; HISTORY OF MEDICINE; HUMAN; HYPERPIGMENTATION; KYPHOSIS; MALE; MEDICAL RECORD REVIEW; OSTEOPENIA; PHYSICAL EXAMINATION; STEROID 21 MONOOXYGENASE DEFICIENCY; TESTIS SIZE; THYROID FUNCTION TEST; URINALYSIS; VERTEBRA FRACTURE;

EID: 77950906940     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2010.23.1-2.179     Document Type: Article

References (39)

1. New MI. An update of congenital adrenal hyperplasia. Ann NY Acad Sci 2004; 1038: 14-43.
2. Nguyen TT, Brown JJ, Warne GL. Growth in CAH. Indian J Pediatr 2006; 73: 89-93.
3. Cameron FJ, Kaymakci B, Byrt EA, Ebeling PR, Warne GL, Wark JD. Bone mineral density and body composition in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1995; 80: 2238-2243.
4. Hagenfeldt K, Ritzen EM, Ringertz H, Helleday J, Carlstrom K. Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy. Eur J Endocrinol 2000; 143: 667-671.
5. Girgis R, Winter JSD. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997; 82: 3926-3929. (Pubitemid 27525488)
6. Jaaskelainen J, Voutilainen R. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol 1996; 45: 707-713. (Pubitemid 27032316)
7. King JA, Wisniewski AB, Bankowski BJ, Carson KA, Zacur HA, Migeon CJ. Long-term glucocorticoid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91: 865-869.
8. Guo CY, Weetman AP, Eastell R. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin Endocrinol 1996; 45: 535-541. (Pubitemid 26411353)
9. Bachelot A, Plu-Bureau G, Thibaud E, Laborde K, Pinto G, Samara D, Nihoul-Fékété C, Kuttenn F, Polak M, Touraine P. Long-term outcome of patients with congenital adrenal hyperplasia due to 21hydroxylase deficiency. Horm Res 2007; 67: 268-276. (Pubitemid 46701492)
10. Stikkelbroeck NMML, Oyen WJG, van der Wilt G-J, Hermus ARMM, Orten BJ. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88: 1036-1042.
11. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007; 119: S166-174.
12. Sciannamblo M, Russo G, Cuccato D, Chiumello G, Mora S. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4453-4458. (Pubitemid 44833422)
13. Loro ML, Sayre J, Roe TF, Goran MI, Kaufman FR, Gilsanz V. Early identification of children predisposed to low peak bone mass and osteoporosis later in life. J Clin Endocrinol Metab 2000; 85: 3908-3918.
14. Speiser PW, New MI, Gertner JM. Increased bone mineral density in congenital adrenal hyperplasia. Pediatr Res 1993; 33: S81.
15. Mora S, Saggion F, Russo G, Weber G, Bellini A, Prinster C, Chiumello G. Bone density in young patients with congenital adrenal hyperplasia. Bone 1996; 18: 337-340. (Pubitemid 26149345)
16. Gussinye M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibanez L, Yeste D. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 1997; 100: 671-674. (Pubitemid 27425992)
17. Fleischman A, Ringelheim J, Feldman HA, Gordon CM. Bone mineral status in children with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2007; 20: 227-235. (Pubitemid 46865073)
18. Sahakitrunggruang T, Wacharasindhu S, Supornsilchai V, Srivuthana S, Kingpetch K. Bone mineral density and body composition in prepubertal and adolescent patients with the classical form of 21-hydroxylase deficiency. J Med Assoc Thai 2008; 91: 705-710. (Pubitemid 351776223)
19. del Rio, L, Carrascosa A, Pons F, et al. Bone mineral density of the lumbar spine in white Mediterranean Spanish children and adolescents: changes related to age, sex, and puberty. Pediatr Res 1994; 355: 364. (Pubitemid 24064613)
20. Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth. Pediatrics 2000; 106: 767-773.
21. Bachelot A, Chakthoura A, Rouxel A, Dulon J, Touraine P. Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults. Horm Res 2008; 69: 203-211. (Pubitemid 351562908)
22. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis Int 2007; 18: 1319-1328.
23. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002; 17: 1512-1526. (Pubitemid 34803834)
24. Pennisi P, Trombetti A, Rizzoli R. Glucocorticoidinduced osteoporosis and its treatment. Clin Orthop Relat Res 2006; 443: 39-47.
25. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79: 127-137.
26. Hansen JW, Loriaux DL. Variable efficacy of glucocorticoids in congenital adrenal hyperplasia. Pediatrics 1976; 57: 942-947.
27. Ceve G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta 2004; 1663: 61-73. (Pubitemid 38625580)
28. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365: 2125-2136.
29. Makitie O, Doria AS, Henriques F, Cole WG, Compeyrot S, Silverman E, Laxer R, Daneman A, Sochett EB. Radiographic vertebral morphology: a diagnostic tool in pediatric osteoporosis. J Pediatr 2005; 146: 395-401. (Pubitemid 40341752)
30. Valta H, Lahdenne P, Jalanko H, Aalto K, Mäkitie O. Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis. J Rheumatol 2007; 34: 831-836. (Pubitemid 46641393)
31. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997; 112: 1710-1713. (Pubitemid 27181398)
32. Acott PD, Crocker JF, Wong JA. Decreased bone mineral density in the pediatric renal transplant population. Pediatr Transplant 2003; 7: 342-344. (Pubitemid 37295938)
33. van der Eerden AW, den Heijer M, Oyen WJ, Hermus AR. Cushing's syndrome and bone mineral density: lowest z scores in young patients. Neth J Med 2007; 65: 137-141.
34. Grigoryan M, Guermazi A, Roemer FW, Delmas PD, Genant HK. Recognizing and reporting osteoporotic fractures. Eur Spine J 2003; Suppl 2: S104-112. (Pubitemid 37409928)
35. Jacobs-Kosmin D, Sandorfi N, Murray H, Abruzzo JL. Vertebral deformities identified by vertebral fracture assessment: associations with clinical characteristics and bone mineral density. J Clin Densitom 2005; 8: 267-272.
36. Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporosis Int 2007; 18: 61-70.
37. Lewiecki EM, Laster AJ. Clinical applications of vertebral fracture assessment by dual-energy X-ray absorptiometry. J Clin Endocrinol Metab 2006; 91: 4215-4222.
38. Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoidinduced osteoporosis. Endocr J 2006; 53: 27-34.
39. Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A. Osteopenia in men with a history of delayed puberty. N Engl J Med 1992; 326: 600-604.